000292117 001__ 292117
000292117 005__ 20250228163922.0
000292117 0247_ $$2doi$$a10.1016/j.mcpro.2024.100825
000292117 0247_ $$2pmid$$apmid:39111711
000292117 0247_ $$2ISSN$$a1535-9476
000292117 0247_ $$2ISSN$$a1535-9484
000292117 0247_ $$2altmetric$$aaltmetric:166018317
000292117 037__ $$aDKFZ-2024-01616
000292117 041__ $$aEnglish
000292117 082__ $$a610
000292117 1001_ $$0P:(DE-He78)154b320ef9a6e95f0081a85ef24eb3a3$$aSalek, Mogjiborahman$$b0$$eFirst author
000292117 245__ $$aoptiPRM: A targeted immunopeptidomics LC-MS workflow with ultra-high sensitivity for the detection of mutation-derived tumor neoepitopes from limited input material.
000292117 260__ $$aBethesda, Md.$$bThe American Society for Biochemistry and Molecular Biology$$c2024
000292117 3367_ $$2DRIVER$$aarticle
000292117 3367_ $$2DataCite$$aOutput Types/Journal article
000292117 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1740749185_28369
000292117 3367_ $$2BibTeX$$aARTICLE
000292117 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000292117 3367_ $$00$$2EndNote$$aJournal Article
000292117 500__ $$a#EA:D410#LA:D410# / HI-TRON / 2024, 23(9), art. no. 100825
000292117 520__ $$aPersonalized cancer immunotherapies such as therapeutic vaccines and adoptive transfer of T cell receptor (TCR)-transgenic T cells rely on the presentation of tumor-specific peptides by human leukocyte antigen (HLA) class I molecules to cytotoxic T cells. Such neoepitopes can for example arise from somatic mutations and their identification is crucial for the rational design of new therapeutic interventions. Liquid chromatography mass spectrometry (LC-MS)-based immunopeptidomics is the only method to directly prove actual peptide presentation and we have developed a parameter optimization workflow to tune targeted assays for maximum detection sensitivity on a per peptide basis, termed optiPRM. Optimization of collision energy using optiPRM allows for improved detection of low abundant peptides that are very hard to detect using standard parameters. Applying this to immunopeptidomics, we detected a neoepitope in a patient-derived xenograft (PDX) from as little as 2.5×106 cells input. Application of the workflow on small patient tumor samples allowed for the detection of five mutation-derived neoepitopes in three patients. One neoepitope was confirmed to be recognized by patient T cells. In conclusion, optiPRM, a targeted MS workflow reaching ultra-high sensitivity by per peptide parameter optimization, which makes the identification of actionable neoepitopes possible from sample sizes usually available in the clinic.
000292117 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000292117 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000292117 7001_ $$0P:(DE-He78)1dfe5fa05989d8b5eeb8bd098e2f1c1f$$aFörster, Jonas$$b1$$eFirst author$$udkfz
000292117 7001_ $$0P:(DE-He78)45aa4fa7b16296bd3454cc3b68c33fc1$$aBecker, Jonas$$b2$$eFirst author$$udkfz
000292117 7001_ $$0P:(DE-He78)27b8b96bde8e36bbbc5e91485b08411a$$aMeyer, Marten$$b3$$udkfz
000292117 7001_ $$0P:(DE-He78)8dde8d3920dc06c59314abdb4ac7d2e8$$aCharoentong, Pornpimol$$b4$$udkfz
000292117 7001_ $$0P:(DE-He78)558f7ddc9b9893d0f57eb74e243cc4fd$$aLyu, Yanhong$$b5$$udkfz
000292117 7001_ $$0P:(DE-He78)9c599f876c762bc78d289674c15ba4a5$$aLindner, Katharina$$b6$$udkfz
000292117 7001_ $$0P:(DE-He78)79e0f95df4135ee2987f9fb4caa77f49$$aLotsch, Catharina$$b7$$udkfz
000292117 7001_ $$aVolkmar, Michael$$b8
000292117 7001_ $$0P:(DE-He78)b2290261145f21c46f2d42783c69d104$$aMomburg, Frank$$b9$$udkfz
000292117 7001_ $$0P:(DE-He78)e9c55f46b4b06cf835834ee7e3e00db8$$aPoschke, Isabel$$b10$$udkfz
000292117 7001_ $$0P:(DE-He78)f0144d171d26dbedb67c9db1df35629d$$aFröhling, Stefan$$b11
000292117 7001_ $$0P:(DE-HGF)0$$aSchmitz, Marc$$b12
000292117 7001_ $$0P:(DE-He78)81ae96953d6149e4307057d71a190019$$aOffringa, Rienk$$b13$$udkfz
000292117 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b14$$udkfz
000292117 7001_ $$0P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aJäger, Dirk$$b15$$udkfz
000292117 7001_ $$0P:(DE-He78)e00d6a13ce5ea2af7bde67bac1319dd3$$aZörnig, Inka$$b16$$udkfz
000292117 7001_ $$0P:(DE-He78)3743a1b712edca2ffa829b7096d7037e$$aRiemer, Angelika$$b17$$eLast author$$udkfz
000292117 773__ $$0PERI:(DE-600)2071375-7$$a10.1016/j.mcpro.2024.100825$$gp. 100825 -$$n9$$p100825$$tMolecular & cellular proteomics$$v23$$x1535-9476$$y2024
000292117 8767_ $$8OAD0000461512$$92024-08-06$$d2024-11-11$$eAPC$$jZahlung erfolgt
000292117 909CO $$ooai:inrepo02.dkfz.de:292117$$popenCost$$pOpenAPC$$pVDB
000292117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)154b320ef9a6e95f0081a85ef24eb3a3$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000292117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1dfe5fa05989d8b5eeb8bd098e2f1c1f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000292117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)45aa4fa7b16296bd3454cc3b68c33fc1$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000292117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)27b8b96bde8e36bbbc5e91485b08411a$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000292117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8dde8d3920dc06c59314abdb4ac7d2e8$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000292117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)558f7ddc9b9893d0f57eb74e243cc4fd$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000292117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9c599f876c762bc78d289674c15ba4a5$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000292117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79e0f95df4135ee2987f9fb4caa77f49$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000292117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2290261145f21c46f2d42783c69d104$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000292117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e9c55f46b4b06cf835834ee7e3e00db8$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000292117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f0144d171d26dbedb67c9db1df35629d$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000292117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000292117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)81ae96953d6149e4307057d71a190019$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000292117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000292117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000292117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e00d6a13ce5ea2af7bde67bac1319dd3$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000292117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3743a1b712edca2ffa829b7096d7037e$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000292117 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000292117 9141_ $$y2024
000292117 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000292117 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000292117 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
000292117 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
000292117 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL CELL PROTEOMICS : 2022$$d2023-10-24
000292117 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000292117 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000292117 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000292117 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:49:13Z
000292117 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:49:13Z
000292117 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T14:49:13Z
000292117 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000292117 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-24
000292117 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000292117 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000292117 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-24
000292117 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-24
000292117 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000292117 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOL CELL PROTEOMICS : 2022$$d2023-10-24
000292117 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-24
000292117 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-24
000292117 9202_ $$0I:(DE-He78)D410-20160331$$kD410$$lImmuntherapie und -prävention$$x0
000292117 9201_ $$0I:(DE-He78)D410-20160331$$kD410$$lImmuntherapie und -prävention$$x0
000292117 9201_ $$0I:(DE-He78)D121-20160331$$kD121$$lAG Antigenpräsentation und T/NK-Zell-Akt$$x1
000292117 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lAngewandte Tumor-Immunität$$x2
000292117 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000292117 9201_ $$0I:(DE-He78)D170-20160331$$kD170$$lKKE Neuroimmunologie und Hirntumorimmunologie$$x4
000292117 9201_ $$0I:(DE-He78)B340-20160331$$kB340$$lTranslationale Medizinische Onkologie$$x5
000292117 9201_ $$0I:(DE-He78)DD01-20160331$$kDD01$$lDKTK Koordinierungsstelle Dresden$$x6
000292117 9201_ $$0I:(DE-He78)D200-20160331$$kD200$$lMolekulare Grundlagen Gastrointestinaler Tumoren$$x7
000292117 9200_ $$0I:(DE-He78)D410-20160331$$kD410$$lImmuntherapie und -prävention$$x0
000292117 980__ $$ajournal
000292117 980__ $$aVDB
000292117 980__ $$aI:(DE-He78)D410-20160331
000292117 980__ $$aI:(DE-He78)D121-20160331
000292117 980__ $$aI:(DE-He78)D120-20160331
000292117 980__ $$aI:(DE-He78)HD01-20160331
000292117 980__ $$aI:(DE-He78)D170-20160331
000292117 980__ $$aI:(DE-He78)B340-20160331
000292117 980__ $$aI:(DE-He78)DD01-20160331
000292117 980__ $$aI:(DE-He78)D200-20160331
000292117 980__ $$aAPC
000292117 980__ $$aUNRESTRICTED
000292117 9801_ $$aAPC